Vaccitech
  • Home
  • About
    • Approach
    • Our Team
  • Technology
  • Portfolio
  • Partnerships
  • Newsroom
  • Careers
  • Contact
Select Page
  • News & Updates
    Learn more
HELLO WORLD
ILLUSTRATOR
WRITER
WEB-DESIGNER

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

Jun 5, 2018

View/Download ASCO 2018 Poster

Recent Posts

  • Vaccitech licenses MERS rights to Oxford University: CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines
  • New UK-China biotech collaboration to develop shingles vaccine
  • Vaccitech are looking for a Manufacturing Project Manager
  • VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine
  • Phase 1 Data on the Vaccitech Prostate Cancer Vaccine Presented at ASCO 2018

Vaccitech Limited

The Schrodinger Building
Heatley Road
The Oxford Science Park
Oxford
OX4 4GE

T: +44 01865 818808

  • Home
  • About
  • Sitemap
  • Privacy Policy
  • Privacy Notice
  • Careers
  • Contact

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world.

© Vaccitech 2018 All rights reserved. Website by Brand Cooke